Highest-materiality recent filing
Certara CFO John Gallagher resigns; Faiz Mohammed named Interim CFO; FY2026 guidance reaffirmed
John Gallagher resigns as CFO effective July 14, 2026 to pursue another opportunity; no disagreement with management.
Certara stockholders elect directors, ratify auditor, approve say-on-pay
All three Class III directors elected: Bedi 121.7M for, McLean 99.9M for (22.9M withheld), Resnick 121.7M for.
Certara Q1 revenue $106.9M (+1%), net loss $8.8M; divests Regulatory Writing for $85M cash
Revenue $106.9M (+1% YoY); software revenue $49.7M (+7%), services revenue $57.2M (-4%).
Certara sells Regulatory & Medical Writing business to Veristat for up to $135M
Cash consideration of $100M plus up to $35M earn-out based on future performance.
Director Cynthia Collins resigns from Certara board, effective May 14, 2026
Cynthia Collins notified her resignation as Class II director and Audit Committee member, effective at the 2026 annual meeting.
Certara Q4 revenue $103.6M (+3%), net loss $5.9M; appoints Jon Resnick CEO; FY26 rev growth 0-4%
Q4 2025 revenue $103.6M (+3% YoY); software revenue $46.4M (+10%), services $57.3M (-1%).
Certara appoints Jon Resnick as CEO effective Jan 1, 2026; Feehery departs Dec 31
Jon Resnick, former IQVIA US/Canada President, named CEO effective Jan 1, 2026; William Feehery steps down Dec 31, 2025.
Certara Q3 2025 revenue $104.6M (+10% YoY); net income $1.5M vs loss; guidance raised
Revenue $104.6M, +10% YoY; software $43.8M (+22%), services $60.8M (+3%).
Certara refinances $296.25M term loans at lower interest rates
Sixth Amendment reduces margin on term loans to SOFR+2.75% or ABR+1.75%.
Certara Q2 2025 revenue $104.6M (+12% YoY); net loss narrows to $2.0M; reiterates FY guidance
Revenue $104.6M (+12% YoY); software revenue $46.7M (+22%), services $57.9M (+5%).
Certara shareholders elect four Class II directors, ratify auditor, approve say-on-pay
Directors elected: Eran Broshy (101.4M for, 44.5M withheld), Cynthia Collins (135.1M for), John Reynders (145.5M for), Matthew Walsh (131.7M for).
Certara Q1 2025 revenue up 10% to $106M; net income positive vs year-ago loss
Revenue $106.0M (+10% YoY); software rev $46.4M (+18%), services $59.6M (+4%).
Certara reports Q1 preliminary revenue up 10% to $106M; $100M buyback authorized
Preliminary Q1 revenue $106.0M (+10% YoY); software revenue $46.4M (+18%), services $59.6M (+4%).
Certara President Patrick F. Smith steps down, moves to senior advisory role
Dr. Patrick F. Smith stepped down as President, Certara Drug Development Solutions, effective March 3, 2025.
Certara Q4 revenue +14% to $100.4M; net income turns positive; guides 2025 margins
Q4 revenue $100.4M (+14% YoY); software rev $42.3M (+26%), services $58.1M (+7%).
Certara reports preliminary Q4 revenue $99.7M (+13% YoY); FY revenue $384.4M (+8%)
Q4 revenue $99.7M vs $88.0M YoY; software +24% to $41.6M, services +7% to $58.1M.
Certara Q3 rev $94.8M (+11% YoY); net loss narrows to $1.4M; guides FY24
Revenue $94.8M (+11% YoY); software rev $35.9M (+15%), services rev $58.9M (+9%).
Certara appoints Dr. John V. W. Reynders to Board of Directors, effective Oct 16, 2024
Dr. Reynders appointed as Class II director and Audit Committee member, effective immediately.
Certara Q2 2024 revenue $93.3M (+3% YoY); net loss $12.6M vs profit prior year
Total revenue $93.3M, up 3% YoY; software revenue $38.2M (+13%), services revenue $55.1M (-3%).
Certara amends bylaws to remove former majority stockholder provisions
On July 17, 2024, Board approved amended and restated Bylaws, effective same day.
Certara signs definitive agreement to acquire Chemaxon; reiterates 2024 guidance
Definitive agreement to acquire Chemaxon, a cheminformatics software provider; no deal value disclosed.
Certara refinances credit facility; extends term loan maturity to 2031, revolver to 2029
Total new term loans of $300M (including $5M incremental) refinance existing debt and fund general corporate purposes.
Certara shareholders elect directors, approve charter amendments, ratify auditor at annual meeting
Elected Class I directors: Cashman (97.7M for), Killefer (116.4M), Spaight (134.1M); all supported.
Certara Q1 revenue $96.7M +7% YoY; net loss $4.7M, reiterates FY guidance
Revenue $96.7M (+7% YoY); software rev $39.3M (+19%), services $57.3M (flat).
Certara Q4 revenue $88M (+2% YoY); net loss of $12.5M vs $9.2M income in prior year
Net loss includes $12.8M increase in fair value of contingent consideration remeasurement related to Vyasa Analytics.
Certara Q3 revenue up 1% to $85.6M; net loss $49.0M on $47M goodwill impairment
Revenue $85.6M (+1% YoY); regulatory revenue declined but biosimulation demand stable.
Certara Q2 revenue $90.5M, net income $4.7M; lowers FY2023 outlook
Revenue $90.5M (+9% YoY, +10% constant currency); net income $4.7M vs loss $0.6M.
Elected William Feehery, Rosemary Crane, and Stephen McLean as Class III directors with 130.4M, 133.1M, and 104.9M for votes respectively.
Certara Q1 revenue $90.3M (+11% YoY); net income $1.4M, down 39%; reiterates 2023 guidance
Revenue $90.3M, up 11% YoY (13% constant currency); net income $1.4M, down 39% vs Q1 2022.
Certara modifies 2022 PSU targets; caps maximum payout at 100% for 2023-2024
Compensation Committee modified 2022 PSU award agreements for all participants including CEO, CFO, and NEOs.
Certara appoints John Gallagher as CFO effective April 1, 2023; Schemick transitions to new role
John Gallagher named CFO, effective April 1, 2023, succeeding Andrew Schemick.
Certara reports Q4 revenue $86.6M (+15% YoY); net income $9.2M vs loss year ago
Q4 revenue $86.6M, up 15% reported (18% constant currency) from $75.3M in Q4 2021.
Certara director Mason Slaine resigns, effective December 23, 2022
Mason Slaine resigned from the Board for personal reasons, effective Dec 23, 2022.
Arsenal Capital Partners closed $449M purchase of 29,954,521 shares from EQT at $15.00/share.
Arsenal Capital Partners commits $449M to buy ~30M Certara shares at $15/sh; expects 22% ownership
Arsenal will acquire ~30M shares from EQT at $15/share, total $449M; subject to HSR regulatory approval.
Certara Q3 revenue up 15% to $84.7M; Arsenal to acquire EQT's 30M shares at $15/share
Revenue $84.7M (+15% YoY); net income $3.9M vs loss $1.8M; adjusted EBITDA $32.7M (+25%).
Certara enters underwriting agreement for secondary offering of 7M shares by selling stockholders
7,000,000 shares of common stock offered by selling stockholders; underwriters have 30-day option for 1,050,000 additional shares.
Justin Edge, President of Regulatory and Access, resigned effective September 1, 2022.
Certara Q2 revenue $82.8M (+18% YoY); guides FY22 lower on FX, regulatory softness
Revenue $82.8M, up 18% reported or 21% constant currency; excluding Pinnacle 21, up 8% reported.
Certara appoints Rosemary A. Crane to Board of Directors
Board increased from 10 to 11 members, creating a new Class III vacancy.
Certara expands board to 10, appoints Eran Broshy as Class III director
Board increased from 9 to 10 members effective July 11, 2022.
Class II directors elected: Cynthia Collin, Eric C. Liu, Matthew M. Walsh to serve until 2025.
Certara Q1 revenue $81.6M (+22% YoY), net income $2.2M, adj EBITDA $27.7M
Revenue $81.6M, up 22% YoY; excluding Pinnacle 21, up 13% to $75.6M.
Director Carol Gallagher resigns from Certara board effective April 5, 2022
Dr. Carol Gallagher resigned for personal reasons, effective April 5, 2022.
Certara dismisses auditor CohnReznick, engages RSM after adverse internal control opinion for FY2021
Audit Committee approved dismissal of CohnReznick effective upon filing Q1 2022 10-Q; RSM engaged for FY2022 subject to acceptance.
Q4 2021 revenue $75.3M, up 17% YoY; net loss $9.7M vs $54.5M loss in Q4 2020.
Certara Q3 revenue $73.9M (+23% YoY), raises FY21 guidance, acquires Pinnacle 21 for $250M
Revenue $73.9M, up 23% YoY; net loss $1.8M vs net income $1.2M in Q3 2020.
Certara completes $310M acquisition of Pinnacle 21, a clinical data compliance SaaS provider
Enterprise value $310M; ~$250M cash + 2,239,717 restricted shares to equityholders.
Certara acquires Pinnacle 21 for $310M in cash and stock
Enterprise value $310M: $250M cash + $60M in newly issued Certara shares.
Certara Q2 revenue $70.1M (+15% YoY); acquires Pinnacle 21 for $310M; raises FY guidance
Revenue $70.1M, +15% YoY; net loss $2.9M vs net income $2.8M in Q2 2020.
On June 11, 2026, John E. Gallagher III, Senior Vice President and Chief Financial Officer of Certara, Inc. (the “Company”), tendered his notice of resignation to the Company to pursue another opportunity.
On June 17, 2026, the Company appointed Faiz Mohammed as its Interim Chief Financial Officer and as both principal financial officer and principal accounting officer of the Company for purposes of the Securities Exchange Act of 1934, as amended, effective as of the Effective Date and until a successor may be appointed.
On March 5, 2025, Certara, Inc. (the “Company”) announced that Dr. Patrick F. Smith, President, Certara Drug Development Solutions, stepped down from that role as of March 3, 2025, but will remain employed by the Company in a senior advisory and scientific role.
On October 16, 2024, the Board of Directors (the “Board”) of Certara, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, voted to appoint Dr. John V. W. Reynders as a Class II director of the Board and a member of the Audit Committee of the Board, effective immediately.
John E. Gallagher III has been appointed as the Company’s Chief Financial Officer, effective April 1, 2023.
M. Andrew Schemick, the Company’s current Chief Financial Officer, who will be stepping down from that role at the end of the day on March 31, 2023, but will remain with the Company in a senior executive role.
On December 23, 2022, Mr. Mason Slaine, a member of the Board of Directors of Certara, Inc. (the “Company”), and a member of the Nominating and Corporate Governance Committee notified the Company of his intention to resign as a director of the Company for personal reasons, effective December 23, 2022.
Also on December 8, 2022, David Spaight was appointed to the Board, effective upon the closing, as a Class I director with a term expiring at the Company’s 2024 Annual Meeting of Shareholders, and Mr. Spaight was appointed to serve as a member of the Board’s Compensation Committee, effective upon the closing.
On December 8, 2022, in connection with the closing of the Sale Transaction (as defined below) (the “closing”), Eric Liu and Ethan Waxman, each a member of the Board of Directors (the “Board”) of Certara, Inc. (the “Company”), each notified the Company of his decision to resign as a director of the Company, effective upon the closing.
On December 8, 2022, in connection with the closing of the Sale Transaction (as defined below) (the “closing”), Eric Liu and Ethan Waxman, each a member of the Board of Directors (the “Board”) of Certara, Inc. (the “Company”), each notified the Company of his decision to resign as a director of the Company, effective upon the closing.
Eric Liu and Ethan Waxman are each expected to resign from the Board following the closing.
Arsenal intends to nominate David Spaight to the Board following the closing and the departure of Mssrs. Liu and Waxman from the Board.
Max materiality 0.90 · Median 0.65 · Most common event earnings